Atrial Fibrillation (AF) is an irregular heartbeat and is the most common form of cardiac arrhythmia affecting approximately 900,000 people in England, (1.74% of the population). National data suggests AF accounts for approximately 20% of all strokes.
In North West London (NWL), Public Health England estimates there are more than 17,000 people with undiagnosed AF. This results in a considerably higher risk of AF-related strokes for those not undergoing treatment. We know that over 4,300 patients with identified AF in NWL and at a high risk of stroke are not on the anticoagulation treatment recommended in NICE Guideline CG180.
AF can be controlled with drug treatments to prevent further complications, predominantly strokes. Anticoagulants alleviate symptoms and reduce the risk of a stroke. Anticoagulants may also be used with antiarrhythmics, slowing down or maintaining a healthy heart rhythm.
As part of the pan-London AF programme, we aim to prevent AF-related stroke and associated mortality through better identification and management of people with AF. This will be achieved through:
- Increasing anticoagulation of untreated high-risk AF patients;
- Improving the quality of anticoagulation;
- Increasing the detection of undiagnosed AF in high-risk patients.
From April 2017 we will publish a range of tools and services on this page, supporting partners in the delivery of best practice anticoagulation.
|Opportunity Analysis||The AF Opportunity Analysis tool is for all CCGs across England to target their resources appropriately, by comparing and analysing their modeled AF targets on a practice-level basis.||April 2017|
|AF Intervention||The Atrial Fibrillation (AF) Intervention is a collection of all the projects we have been working on with our partners. We have analysed the different sections that make up the AF pathway where improvement could be made.||May 2017|
|Business Case Model Template||The Atrial Fibrillation (AF) Business Case Model uses published data regarding primary care performance against QOF targets, together with estimated prevalence data to compare current management of AF with optimal goals.||June 2017|
|Track and Evaluation||Coming soon||July 2017|
|Gap Analysis||Coming soon||August 2017|
|New Data Analysis||Coming soon||September 2017|